{"DataElement":{"publicId":"3192464","version":"1","preferredName":"Person Monoclonal Antibody VEGFR Tyrosine Kinase Inhibitor Discontinue Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator whether there was discontinuation of monoclonal antibody therapy, therapy using an antibody produced by a clone or genetically homogenous population of hybrid cells that are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous, or vascular endothelial growth factor receptor inhibition therapy, therapy that blocks an enzyme needed to form blood vessels, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"3192293v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3192293","version":"1","preferredName":"Person Monoclonal Antibody VEGFR Tyrosine Kinase Inhibitor Discontinue Clinical Trial Eligibility Criteria","preferredDefinition":"information related to the discontinuation of monoclonal antibody therapy, therapy using an antibody produced by a clone or genetically homogenous population of hybrid cells that are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous, or vascular endothelial growth factor receptor inhibition therapy, therapy that blocks an enzyme needed to form blood vessels, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3192291v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3192291","version":"1","preferredName":"Monoclonal Antibody VEGFR Tyrosine Kinase Inhibitor Discontinued Clinical Trial Eligibility Criteria","preferredDefinition":"An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.:A substance that blocks an enzyme needed to form blood vessels.:Discontinued; stopped permanently or temporarily.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C20401:C93259:C25484:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"VEGFR Tyrosine Kinase Inhibitor","conceptCode":"C93259","definition":"Any substance that inhibits vascular endothelial growth factor receptor, a family of tyrosine kinase receptors involved in the formation of blood vessels.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C6A279D-5F49-9900-E040-BB89AD430342","latestVersionIndicator":"Yes","beginDate":"2011-02-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-16","modifiedBy":"ONEDATA","dateModified":"2011-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C6A279D-5F5A-9900-E040-BB89AD430342","latestVersionIndicator":"Yes","beginDate":"2011-02-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-16","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000081","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"4104906","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"10000082","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"10000430","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"10000429","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"4104905","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"10000346","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000345","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104907","version":"1","longName":"GOG-0186K","context":"NRG"}]}],"AlternateNames":[{"name":"GOG","type":"USED_BY","context":"NRG"},{"name":"3192293v1.0:2018257v1.0","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Have all chimeric or human or","type":"Preferred Question Text","description":"Have all chimeric or human or humanized monoclonal antibodies (including Bevacizumab) or VEGF receptor fusion proteins (including VEGF Trap/aflibercept) been discontinued for at least 12 weeks prior to today?","url":null,"context":"CTEP"},{"name":"GOG_CRF Text","type":"Alternate Question Text","description":"Will all chimeric or human or humanized monoclonal antibodies (including Bevacizumab) or VEGF receptor fusion proteins (including VEGF Trap/aflibercept) been discontinued for at least 12 weeks prior to start of study treatment?","url":null,"context":"NRG"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Has the patient completed prior therapy with monoclonal antibody(ies) at least 28 days prior to registration?","url":null,"context":"CTEP"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Has the patient completed prior therapy with monoclonal antibody(ies) at least 28 days prior to Step 2 registration?","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C7BAA00-4681-500E-E040-BB89AD431E24","latestVersionIndicator":"Yes","beginDate":"2011-02-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-17","modifiedBy":"BOWSERC","dateModified":"2021-12-09","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}